Law Firms Investigate Veracyte Over Decipher Outlook Statements

The investigations follow a report of lower-than-expected Decipher Prostate test volumes and reduced 2026 revenue guidance. Veracyte narrowed its revenue outlook to $590–$593 million from $590–$596 million and cut its annual incremental Decipher volume projection to 12,000–15,000 tests. The company also authorized a $100 million share repurchase.